{"id":10723,"date":"2024-10-25T15:36:58","date_gmt":"2024-10-25T08:36:58","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=10723"},"modified":"2024-10-25T15:36:58","modified_gmt":"2024-10-25T08:36:58","slug":"everest-medicines-announces-the-launch-of-velsipity-in-the-guangdong-hong-kong-macau-greater-bay-area-offering-a-new-option-for-moderately-to-severely-active-ulcerative-colitis-patients","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=10723","title":{"rendered":"Everest Medicines Announces the Launch of VELSIPITY\u00ae in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients"},"content":{"rendered":"

SHANGHAI<\/span><\/span>, Oct. 25, 2024<\/span><\/span> \/PRNewswire\/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced\u00a0that, through the “Hong Kong<\/span> and Macau Medicine and Equipment Connect” policy, VELSIPITY\u00ae has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat<\/span>-sen University, two of the medical institutions designated by the “Hong Kong<\/span> and Macau Medicine and Equipment Connect” policy in the Greater Bay Area. Subsequently, VELSIPITY\u00ae will be introduced in other qualified hospitals under the connect policy. VELSIPITY\u00ae\u00a0is now the third commercialized product of Everest Medicines.<\/p>\n

VELSIPITY\u00ae is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau<\/span> in April 2024<\/span>. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China<\/span> is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.<\/p>\n

“The launch of VELSIPITY\u00ae in the Greater Bay Area accelerates the access to this advanced therapy in mainland China<\/span>, offering a new option for patients with moderately to severely active UC.” Said Rogers Yongqing Luo<\/span>, Chief Executive Officer of Everest Medicines. “Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY\u00ae submitted for new drug application in mainland China<\/span> by the end of this year, further enhancing its accessibility and benefiting more patients.”<\/p>\n

VELSIPITY\u00ae was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY\u00ae in Greater China<\/span> and South Korea<\/span> from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY\u00ae was successively approved in Macau<\/span> and Singapore<\/span> in the first half of this year and was approved in the United States<\/span> and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY\u00ae in Hong Kong, China<\/span>.<\/p>\n

VELSIPITY\u00ae is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY\u00ae for the treatment of moderately to severely active UC announced in July this year, VELSIPITY\u00ae achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.<\/p>\n

About VELSIPITY\u00ae\u00a0(etrasimod)<\/strong><\/p>\n

VELSIPITY\u00ae\u00a0is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada<\/span>, Australia<\/span>, Singapore<\/span>, UK, Switzerland<\/span>, Israel<\/span> and Macau<\/span> for VELSIPITY\u00ae in ulcerative colitis.<\/p>\n

About Everest Medicines<\/strong><\/p>\n

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com<\/a>.<\/p>\n

Forward-Looking Statements:<\/strong><\/p>\n

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SHANGHAI<\/span><\/span>, Oct. 25, 2024<\/span><\/span> \/PRNewswire\/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced\u00a0that, through the “Hong Kong<\/span> and Macau Medicine and Equipment Connect” policy, VELSIPITY\u00ae has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat<\/span>-sen University, two of the medical institutions designated by the “Hong Kong<\/span> and Macau Medicine and Equipment Connect” policy in the Greater Bay Area. Subsequently, VELSIPITY\u00ae will be introduced in other qualified hospitals under the connect policy. VELSIPITY\u00ae\u00a0is now the third commercialized product of Everest Medicines.<\/p>\n

VELSIPITY\u00ae is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau<\/span> in April 2024<\/span>. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China<\/span> is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.<\/p>\n

“The launch of VELSIPITY\u00ae in the Greater Bay Area accelerates the access to this advanced therapy in mainland China<\/span>, offering a new option for patients with moderately to severely active UC.” Said Rogers Yongqing Luo<\/span>, Chief Executive Officer of Everest Medicines. “Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY\u00ae submitted for new drug application in mainland China<\/span> by the end of this year, further enhancing its accessibility and benefiting more patients.”<\/p>\n

VELSIPITY\u00ae was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY\u00ae in Greater China<\/span> and South Korea<\/span> from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY\u00ae was successively approved in Macau<\/span> and Singapore<\/span> in the first half of this year and was approved in the United States<\/span> and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY\u00ae in Hong Kong, China<\/span>.<\/p>\n

VELSIPITY\u00ae is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY\u00ae for the treatment of moderately to severely active UC announced in July this year, VELSIPITY\u00ae achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.<\/p>\n

About VELSIPITY\u00ae\u00a0(etrasimod)<\/strong><\/p>\n

VELSIPITY\u00ae\u00a0is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada<\/span>, Australia<\/span>, Singapore<\/span>, UK, Switzerland<\/span>, Israel<\/span> and Macau<\/span> for VELSIPITY\u00ae in ulcerative colitis.<\/p>\n

About Everest Medicines<\/strong><\/p>\n

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com<\/a>.<\/p>\n

Forward-Looking Statements:<\/strong><\/p>\n

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-10723","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/10723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10723"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/10723\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}